Oruka Therapeutics

top of page

Apr 3

Spun out of Paragon, Oruka Therapeutics raised $275M today as part of a reverse merger to tackle skin conditions in the I&I space

CEO Lawrence Klein describes advances in antibody engineering Oruka is leveraing to make improved IL-23 and IL-17 inhibitors.

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh